CAR-T里程碑式专利
WO2005044996
St. Jude Children's Research Hospital
Chimeric receptors with 4-1BB stimulatory signaling domain
US9834590
St. Jude Children's Research Hospital
Chimeric receptors with 4-1BB stimulatory signaling domain
WO2007059298
City of Hope
Chimeric immunoreceptor useful in treating human cancers
WO2008043777
University of Nantes
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
WO2008121420
Memorial Sloan Kettering Cancer Center
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009091826
University of Texas System
Compositions and methods related to a human CD19-specific chimeric antigen receptor (h-CAR)
WO2011056894
City of Hope
Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection
WO2012079000
University of Pennsylvania
Use of chimeric antigen receptor modified T-cells to treat cancer
WO2012129514
Fred Hutchinson Cancer Research Center
Method and compositions for cellular immunotherapy
WO2013123061
Seattle Children's Hospital
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
WO2014153270
Novartis and University of Pennsylvania
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
WO2015142675
Novartis and University of Pennsylvania
Treatment of cancer using chimeric antigen receptor
WO2017025038
Legend Biotech
Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2017172981
University of Southern California
Chimeric antigen receptors targeting cancer
WO2019076149
Chongqing Precision Biotech
Universal CAR-T cell preparation, method therefor and application thereof
CN109055380
Fapon Biopharma
A preparation method for universal CAR-T cells
Top20发明人
Top20 受让人
18位为科济生物
受让者协作关系
美国宾夕法尼亚大学和诺华有最密切的合作关系
将总部位于同一区域的受让人合并,将机构网络转换为区域网络。
地理分布
美国于2005年首次发布CAR-T专利,法国和其他主要国家分别于2008年和2012年发表CAR-T专利。自2017年以来,中国受让人申请的专利数量位居第二,尽管它们仍不到美国专利总数的十分之一。
美国专利局(USPTO)和中国国家知识产权局(CNIPA)一直在提交接近数量的专利申请;2016年中国(n=119)首次超过美国(n=107)。专利申请在欧洲专利局和日本专利局保持了相对稳定的增长趋势。然而,自2018年以来,加拿大收到的专利急剧减少。
靶点分布
前20个靶点, CD19最常见,其次是BCMA和CD20。美国和中国的受让人涵盖了所有靶点,且在所有的顶级靶点都处于领先地位。
引用网络
WO2012079000(使用嵌合抗原受体改造的T细胞治疗癌症)和 WO2014153270(诺华CD19)引用最多。
粉红色簇中主要集中在异基因细胞和相关方法上,如WO2013176915(methods for engineering allogeneic and immunosuppression-resistant T cells for immunotherapy),WO2014191128(methods for engineering T cells for immunotherapy by using an RNA-guided Cas nuclease system)和WO2014039523(multi-chain chimeric antigen receptor and uses thereof)。这三项专利拥有相同的受让人,即法国生物制药公司Celectis。
绿色部分主要来自中国。
喵评:
中国CAR-T细胞治疗飞速发展,并逐渐成为全球第一梯队。南京传奇,上海科济,重庆精准等逐渐获得一席之地。
参考文献:
Liyang Lyu et al,The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape,Nat Biotechnol . 2020 Dec;38(12):1387-1394.
申明:如本站文章或转稿涉及版权等问题,请您及时联系本站,我们会尽快处理!
BioSwan Laboratories, Co., Ltd.
Room 808,
No.781 Cailun Road,
Pudong New District, Shanghai 201203
P. R. China
Customer Service
Information / Ordering
86-21-50207339
info@
Distributor
上海星湾生物技术有限公司 Copyright 2019